Crioprecipitat indicatii

This is especially common in cirrhotic patients, so please remember to check fibrinogen level along with daily PT/PTT testing in appropriate patients Pregnant women have higher fibrinogen levels, and cryoprecipitate transfusion may be indicated at higher levels, such as < 200 mg/dL TEG alpha or K-time below laboratory normal valu Summary of Indications: Transfusion of cryoprecipitate is indicated to treat bleedings on in preparation for an invasive surgical procedure in the following settings: o Replacement of fibrinogen in patients with hypofibrinogenemia (< 100 mg/dL) or dysfibrinogenemi Cryo is generally transfused in pools of 10 units, which should increase an adult recipient's fibrinogen level by 50-100 mg/dL. Pediatric dosing for Cyro is 1 unit per 10kg body weight, which should increase fibrinogen by 60-100 mg/dL. Contact Us. Blood Bank & Transfusion Services. 409-772-8284 As with FFP, the plasma from which the cryoprecipitate was produced has been leucodepleted and was obtained from a male donor to reduce the risk of transfusion-related acute lung injury (TRALI). Cryoprecipitate should be stored at a core temperature of -25°C or below for up to 36 months. Clinical indications for use of cryoprecipitate in adults Other Indications and Uses Cryo is used most commonly for replacement of fibrinogen in patients that are bleeding or at increased risk of bleeding. Fibrinogen replacement may be indicated for hypofibrinogenemia or dysfibrinogenemia whether acquired or congenital

Once thawed, cryoprecipitate should be used within 6 hours if it is a closed single unit, or within 4 hours if it is an open system or units have been pooled. Thawed cryoprecipitate should be maintained at 20-24°C until transfused. For pooling, the precipitate in each concentrate should be mixed well with 10-15 mL of diluent to ensure. Cryoprecipitate, also called cryo for short, is a frozen blood product prepared from blood plasma. To create cryoprecipitate, fresh frozen plasma thawed to 1-6 °C is then centrifuged and the precipitate is collected. The precipitate is resuspended in a small amount of residual plasma (generally 10-15 mL) and is then re-frozen for storage and 10 units of cryoprecipitate. No value in infusing anti-fibrinolytic agents WARFARIN Not Bleeding: Goal is INR in 2-3 range INR Action 3- 4.5 Hold dose until INR decreased 4.5-10 1.25 mg Vitamin K PO > 10 2.5 - 5 mg Vitamin K PO Should see INR back in therapeutic range in 24-48 hour Cryoprecipitate: Indications: 1. Severe liver disease 2. DIC 3. Afibrinogenemia or significant hypofibrinogemia with other associated indications 4. Von Willebrands -2nd line therapy 5. Factor XIII deficienc What Is Cryoprecipitate? Why Is It Important? Cryoprecipitated Antihemophilic Factor, also called cryo, is a portion of plasma, the liquid part of our blood. Cryo is rich in clotting factors, which are proteins that can reduce blood loss by helping to slow or stop bleeding

Cryoprecipitate Transfusion Guidelines - University of

  1. Cryoprecipitate is available in pre-pooled concentrates of five units. Each unit from a separate donor is suspended in 15 mL plasma prior to pooling. For use in small children, up to 4 single units can be ordered. Each unit provides about 325 mG of fibrinogen. Indications for Cryoprecipitat
  2. Clinical indications for useofClinicalcryoprecipitate ofuations. cryoprecipitate in the following sit-rience supports the use levels of fibrinogen activty canReduc edHypodysfibrinogenemia
  3. Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement
  4. Cryoprecipitate (Cryoprecipitated antihemophilic factor [AHF]; cryo) is a plasma-derived blood product for transfusion that contains fibrinogen (factor I), factor VIII, factor XIII, von Willebrand factor, and fibronectin. This topic discusses the clinical use of Cryoprecipitate
  5. Cryoprecipitate Components Cryoprecipitated Antihemophilic Factor (AHF) (cryoprecipitate) contains fibrinogen, Factor VIII, von Willebrand Factor and Factor XIII. Indications for Cryoprecipitate Transfusion 1
  6. †Note: Cryoprecipitate may be indicated for replacement in the case of factor XIII deficiency.2 FFP may also be used, but infusion requires much larger volumes. A factor XIII concentrate has been approved in the U.S. for prophylactic treatment of congenital factor XIII deficiency, but not for bleeding episodes.

  1. Cryoprecipitate Transfusion Dosing Table Pt Wt mL/Kg ORDER in Kg 15 0.4 6 exact mL 0.5 7.5 exact mL 0.6 9 exact mL 0.7 10.5 exact mL 0.8 12 exact mL 0.9 13.5 exact mL 1 15 exact mL 2 1 unit 3 1 unit 4 1 unit 5 1 unit 6 2 units 7 2 units 8 2 units 9 2 units 10 2 units 11 3 units 12 3 units 13 3 units 14 3 units 15 3 units 16 4 units 17 4 units.
  2. Indications for Use. Cryoprecipitate was originally prepared as a source of Factor 8 for hemophilia A patients and to treat patients with von Willebrand's disease. It is no longer the preferred product for treatment of hemophilia A and von Willebrand's disease as coagulation factor concentrates are readily available

Cryoprecipitate has been widely used for a variety of indications surrounding hypofibrinogenemia. Most recently, cryoprecipitate has been recommended for hypofibrinogenemia following administration of alteplase due to the increased risk of parenchymal hematoma following alteplase administration for acute ischemic stroke (AIS) A Brief Overview of Cryoprecipitate. Cryoprecipitated Antihemophilic Factor is more commonly known as cryoprecipitate, or simply cryo. Cryoprecipitate can only be made from Fresh Frozen Plasma (FFP), which has been removed from whole blood and frozen within eight hours of being collected. The FFP is slowly thawed between 1 and 6C Guidelines for cryoprecipitate transfusion have been developed by the Transfusion Medicine Advisory Group of British Columbia to educate clinicians and address transfusion practices in the province. These guidelines are based on a MEDLINE search and consultation with hematopathologists and clinicians. At present, transfusion of cryoprecipitate.

Cryoprecipitate - UTM

Keywords: Cryoprecipitate, Transfusion, Guidelines and Coagulopathy. Introduction Cryoprecipitate is a concentrate of high molecular weight plasma proteins. It is prepared by slowly thawing fresh frozen plasma (FFP) at . 58 G.F. Zaher and S.S. Adam 4°C to 6°C. These results in the formation of an insoluble precipitate tha (Neurovascular Service guidelines for the use of intravenous tPA in acute stroke recommend FFP, cryoprecipitate and platelet transfusions in patients who develop acute neurological deterioration, significant bleeding, or other complications during tPA infusion). Platelet Count <100 k. Patients with head bleed or bleeding into the eye or orbi Cryoprecipitate contains only 10 - 15 mL of plasma and pools of cryoprecipitates have reduced levels of anti-A and anti-B antibody and may be used universally for adult recipients (Shaz: Transfusion Medicine and Hemostasis - Clinical and Laboratory Aspects, 2nd Edition, 2013) Standard adult dosing Cryoprecipitate, pools of 1

Cryoprecipitate: Side Effects, Dosages, Treatment

those for cryoprecipitate production. The basic principles as stated in the WHO consensus statements WHO/LBS/93.2 and WHO/GPA/ INF/93.1 are the same. Some simple guidelines are incorporated into the article as well as guidelines for the collection of donor blood so that maximum factor VIII can be extracted One unit of Cryoprecipitate contains approximately 250 mg of Fibrinogen. Also, it is a VERY concentrated source of Factor 8. How is it prepared? by slowly thawing a unit of FFP at temperatures just above freezing (1-6 °C), typically in a water bath or a refrigerator. The product is then centrifuged to remove the majority of the plasma, and the precipitate is resuspended in the remaining.

Cryoprecipitate • LITFL • CCC Haematolog

cryoprecipitate and plasma-derived fibrinogen concentrates are used to increase fibrinogen levels in patients with fibrinogen consumption and/or loss or for replacement of dysfunctional fibrinogen molecules 1,2; most frequent indication for fibrinogen replacement is in patients with acquired hypofibrinogenemia as result of massive hemorrhage (23782082 Expert Rev Hematol 2013 Jun;6(3):277 Transfusion of cryoprecipitate is indicated for fibrinogen deficiency or dysfibrinogenemia in the setting of hemorrhage, invasive procedures, injury, or acute disseminated intravascular coagulation The BCSH guidelines for use of fresh frozen plasma, cryoprecipitate, and cryosupernatant note that cryoprecipitate is commonly used to enhance fibrinogen levels in dysfibrinogenemia and acquired hypofibrinogenemia in massive transfusion and disseminated intravascular coagulation, where plasma fibrinogen is below 100 mg/dL Cryoprecipitate is used for two clearly defined clinical indications: hemophilia treatment and supplementation of fibrinogen (both inherited and acquired disease; Table 2). 5,10,20 But the way cryoprecipitate is used varies worldwide . 21-23 This variation tends to depend on the availability of fibrinogen concentrate as an alternative. Here is a brief overview of the products and services available: Packed red blood cells (PRBCs) are made from a unit of whole blood by centrifugation and removal of most of the plasma, leaving a unit with a hematocrit of about 60%. One PRBC unit will raise the hematocrit of a standard adult patient by 3% (or about 1%/mL/kg in a child - 12%/25.

Guidelines for cryoprecipitate are based on clinical consensus and can vary between providers and institutions due to the lack of evidence from randomized controlled trials [5, 11,12,13]. With this in mind, it is not a surprise that the clinical indications for the use of cryoprecipitate have changed frequently over the last few decades Spectrum of fresh frozen plasma and cryoprecipitate products. Date: 12 March 2018. Fresh frozen plasma (FFP) is given primarily for three indications: to prevent bleeding (prophylaxis), stop bleeding (therapeutic) or for plasma exchange. Prophylactic transfusions are mainly used prior to surgery or invasive procedures B. Cryoprecipitate Dosing, Administration, and Expected Response 14 VII. Granulocytes A. Preparation 14 B. Indications, Patients < 4 Months of Age 14 C. Indications, Patients ≥ 4 Months of Age 15 VIII. Special Considerations 15 A. RBC age, Preservatives, Hemoglobin S Status 15. Cryoprecipitate for Neonates and Infants, Leucocyte Depleted is the cryoglobulin fraction of plasma obtained by thawing a single donation of Fresh Frozen Plasma, Leucocyte Depleted (see section 7.15), fulfilling the requirements for neonates and infants, at 4 ±2°C. The component should be free from clinically significant irregular blood group.

D. Indications: Hypofibrinogenia, increased risk of bleeding: - Patients with congenital hypofibrinogenemia (< 100 mg/dL) or dysfibrinogenemia - Patients with acquired hypofibrinogenemia, for example DIC (< 100 mg/dL) - most common clinical indication for cryoprecipitat Blood products - cryoprecipitate (Newborn Services) Date last published: 14 August 2018. Cryoprecipitate is prepared by freezing and then thawing plasma at which time a cryoprecipitate occurs which contains a high concentration of factor VIII fibrinogen, fibronectin and factor XIII. This document is only valid for the day on which it is accessed In 2014 and 2015 patients developed TRALI after receiving cryoprecipitate pools containing plasma from female donors, all with concordant antibodies. SHOT recommended that cryoprecipitate should also be sourced from male donors only, as is the case for FFP (Bolton-Maggs et al, 2016), and this has now been put into practice in the UK

Cryoprecipitate - Wikipedi

What Is Cryoprecipitate Red Cross Blood Service

  1. The Patient Blood Management (PBM) Guidelines provide some additional guidance regarding cryoprecipitate use: The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified. (Modules 3 and 4)
  2. Indications for cryoprecipitate transfusion are listed in Table 4.12,15 Each unit will raise the fibrinogen level by 5 to 10 mg per dL (0.15 to 0.29 µmol per L), with the goal of maintain
  3. http://usmlefasttrack.com/?p=5645 Blood, Transfusion, Therapy, -, Packed, RBCs Platelets Fresh, Frozen, Plasma, &, Cryoprecipitate, Findings, symptoms,.
  4. Cryoprecipitate Guideline GRADE criteria Introduction Antithrombotics, including anticoagulants, antiplatelet agents, and thrombolytics are used to treat or decrease the risk of thrombotic or embolic events in a wide variety of medical conditions. With the introduction of new antithrombotics to the market, an aging patient population
  5. Country-specific guidelines and recommendations for the content and use of cryoprecipitate are outlined in Table 2. In the UK, the British Committee for Standards in Haematology state that 75% of packs of cryoprecipitate should contain >140 mg fibrinogen and 70 IU ml −1 FVIII, usually prepared in a volume of 20-40 ml
  6. Blood Volume Calculation Cryoprecipitate Dosing for Fibrinogen Replacement: Donor lymphocyte infusion (dli) volume Mentzer index for thalassemia: Predicting risk of severe complications in a child with sickle cell disease (miller et al) Sickle cell rbc exchange volum
  7. istration of RBCs, platelets, FFP, and cryoprecipitate

Cryoprecipitate - Bloodworks Northwes

  1. The dosing of both cryoprecipitate and fibrinogen concentrate in children should be calculated, taking into consideration the baseline fibrinogen, the child's body weight, the presence of active bleeding and ongoing loss. It is advisable, that after fibrinogen supplementation,.
  2. Guidelines for the use of non-RBC blood components in the early phase of trauma resuscitation are largely based on extensions of expert recommendations for general surgery. Methods: The logic and evidence for the use of plasma, platelets, and cryoprecipitate early in the course of massive transfusion for trauma were reviewed. Large series of.
  3. Fibrinogen is a critical protein for clot formation, providing a matrix and mesh network essential for clot strength. Maintaining fibrinogen levels is an important therapeutic target in bleeding patients, particularly in perioperative settings. 1-3 Early studies demonstrated that fibrinogen repletion corrected clot strength, based on viscoelastic blood testing using thromboelastography.
  4. Guidelines for Use of Canine Blood Components Cryoprecipitate This product is prepared by a controlled thaw of fresh frozen plasma, resulting in a concentration of Factor VIII, Factor XIII, vWF and some fibrinogen. Storage Must be stored at < -18 C (< 32 F). A common household freezer is sufficient for storage. Indication
  5. Indications for Cryoprecipitate Cryoprecipitate is indicated for: Active bleeding and fibrinogen level <1.5 g/L During massive transfusion or cardiac bypass, for the treatment bleeding when the fibrinogen level <1.5 g/L or there is hyperfibrinolysis.
  6. People have the right to be involved in discussions and make informed decisions about their care, as described in making decisions about your care.. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws.
  7. Cryoprecipitate use should be reserved for patients with documented isolated hypofibrinogenemia, but there are few prospective trial data to define the optimal use of cryoprecipitate. There is evidence that the use of cryoprecipitate is rising in many countries, although the exact reasons for this remain unclear

Clinical use of Cryoprecipitate - UpToDat

Cryoprecipitate dosing Guidelines. 1 unit of cryo per 5kg patient weight will increase fibrinogen by about 100 mg/dL Number of bags = 0.2 x weight (kg) to provide about 100mg/dL fibrinogen Many institutions use a standard dose of 10..Every cryo unit ordered may be triaged by transfusion medicine A smaller dose of cryo may need to be given (ie, 5 bags instead of the usual 10 bag dose) Cryoprecipitate is usually licensed by regulatory authorities for the treatment of hypofibrinogenaemia, and recommended for supplementation when plasma fibrinogen levels decrease below 1 g litre −1; however, this threshold is empiric and is not based on solid clinical evidence. Consequently, there is uncertainty over the appropriate dosing. Indications for Pediatric MTP Cryoprecipitate: Fibrinogen based: After one total blood volume has been replaced, check fibrinogen level. If <200 mg/dL, give 10ml/kg of cryoprecipitate.ve 1 unitsNIST of 1ll be provided, the blood bank will notify the attending by phone

The type of coagulation factors and proteins in cryoprecipitate determine the appropriate indications for its use. To determine the pattern of use at a tertiary care medical center, we performed a. Plasma, Cryoprecipitate Reduced. This is the formal name for the plasma product that also has been called cryosupernatant or more commonly, CRYO-reduced Plasma (CRP).. When Fresh Frozen Plasma (FFP) is thawed at 1-6C in a refrigerator, a small amount of the plasma precipitates (becomes slushy or solid) in the bag Cryoprecipitate should be infused through a standard blood filter at a rate of 4 to 10 mL/minute. At this rate, a pool of 10 bags can be infused in approximately 30 minutes. The risk of viral transmission from cryoprecipitate is the same as other plasma products Cryoprecipitate: Goal of cryoprecipitate transfusion is to replace fibrinogen; Contains fibrinogen, vWF, fVIII, fXIII, and fibronectin; 1 unit of cryoprecipitate should increase fibrinogen level by 7-8 mg/dL. 1 unit of FFP has equivalent of 2 units of cryoprecipitate, but at cost of higher volume ; Indications. fibrinogen < 80-100 mg/dL in.

Plasma and Cryoprecipitate - Fairvie

The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows: Decision-making process and recommendations: Due to concerns about the safety and quality of cryoprecipitate, its use in the treatment of congenital bleeding disorders is not recommended and can. Increases Fibrinogen up to 100 mg/dl per dose (15-20 ml per 5-7 kg body weight, or 10 units for 70 kg) Expect one unit to raise Fibrinogen 5-10 mg/dl. Goal Fibrinogen >100 mg/dl. VI. Dosing. Adults: 15-20 ml per 5-7 kg body weight. Typical dose: 10 units Cryoprecipitate. Newborn: variable dosing starting from 2 ml/kg. VII The products above may be re-labeled as Thawed Plasma (note the CAPITAL T and P) and stored under the same conditions as before (i.e., 1-6C) for up to 5 days after thawing (technically, Cryo-reduced plasma must be re-labeled as Thawed Plasma Cryoprecipitate Reduced, but the principle is the same) British Committee for Standards in Haematology 2004 Guidelines for the use of Fresh Frozen Plasma, Cryoprecipitate and Cryosupernatant. British Journal of Haematology 126(1): 11-28 British Committee for Standards in Haematology 2007 Amendment to the Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Available; Guidelines. Read cryoprecipitate guidelines for the UK's blood transfusion services on the Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee (JPAC) website. We also purchase small volume Methylene Blue Treated and removed Cryo from NHS Blood and Transplant (NHSBT)


Cryoprecipitate has a relatively high fibrinogen content; however, as it is produced by pooling fresh frozen donor plasma, the fibrinogen content per unit can vary considerably. Current guidelines suggest that cryoprecipitate use should be limited to treating hypofibrinogenemia in patients with clinical bleeding cryoprecipitate guidelines provided the recommendations in this guideline. The ABC Working Group was convened to provide expert opinion for the guideline and it was presented to stakeholders within Nova Scotia and their feedback was incorporated Cryoprecipitate is a substance that comes from thawing fresh frozen plasma. It is rich in factor VIII (8), and was commonly used to control serious bleeding in the past. However, because there is no method to kill viruses, such as HIV and hepatitis, in cryoprecipitate, it is no longer used as the current standard of treatment in the United States Cryoprecipitate Dose - 2 pooled units, equivalent to 10 individual units, will increase fibrinogen by approximately 1 g/ L. Cryoprecipitate is usually used with FFP unless there is an isolated deficiency of fibrinogen o Dosing is based on factor IX content (in units) and a 1000 unit vial contains a minimum of 1000 units, but frequently contains slightly more (20-40 units) but NEVER less. Pharmacy will prepare the dose with the contents of 2 vials which will ALWAYS be at least 2000 units

The Secrets of Cryoprecipitate: A Blood Banking Process

Cryoprecipitate - an overview ScienceDirect Topic

Guidelines, Responsibilities of Director of Blood Bank, Medical Director of Blood Bank and Director of Transfusion Service, Second Edition Blood bank and transfusion service, director responsibilitie Cryoprecipitate: | |Cryoprecipitate|, also called Cryoprecipitated Antihaemophilic Factor, Cryoprecipitat... World Heritage Encyclopedia, the aggregation of the largest online encyclopedias available, and the most definitive collection ever assembled Cryoprecipitate is a concentrate prepared from fresh frozen plasma. Each concentrate usually contains about 80 units each of factor VIII and von Willebrand factor and about 250 mg of fibrinogen. It also contains ADAMTS13 (an enzyme that is deficient in congenital thrombotic thrombocytopenic purpura), fibronectin, and factor XIII

A Brief Overview of Cryoprecipitate - Carter BloodCar

An order for 10 units of cryoprecipitate for an average sized adult patient is typical at many hospitals (1-2 units of CRYO per every 10kg body weight)9.1 Carefully inspect each bag for signs of cracking or breakage, especially around the ports at the top of the unit Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. It is used to treat conditions in which there are low blood clotting factors (INR > 1.5) or low levels of other blood proteins. It may also be used as the replacement fluid in plasma exchange. Using ABO compatible plasma, while not required, may be recommended. Use as a volume expander is not recommended Start studying FFP, Platelets, and Cryoprecipitate. Learn vocabulary, terms, and more with flashcards, games, and other study tools Fresh Frozen Plasma and Cryoprecipitate. Date : 26 May, 2018. Fresh Frozen Plasma (FFP) is a blood product made from the liquid portion of whole blood, it is used to treat conditions in which there are low blood clotting factors (INR>1.5) or low levels of other blood proteins. FFP was used for the first time during the Second World War

Guidelines for cryoprecipitate transfusion British

Disseminated intravascular coagulation (DIC) is a syndrome characterized by the systemic activation of blood coagulation, which generates intravascular thrombin and fibrin, resulting in the thrombosis of small- to medium-sized vessels and ultimately organ dysfunction and severe bleeding [1, 2].DIC may result as a complication of infection, solid cancers, hematological malignancies, obstetric. The guidelines don't actually discuss central venous catheter insertion, but central line insertion seems to be a lower-risk procedure compared to thoracentesis. The best approach to limiting bleeding: Use the smallest bore needle possible (e.g., a 24-gauge lumbar puncture needle is adequate for diagnostic paracentesis)


Blood utilization principles. Blood product transfusion thresholds must be strictly followed, and all product release outside of these thresholds will require approval of pathology staff. If a blood product order does not meet a transfusion threshold or there is a critical shortage, the order will be triaged and the ordering physician will be. RiaSTAP dosing, duration of dosing, and frequency of administration should be individualized based on the extent of bleeding, laboratory values, and the clinical condition of the patient. When the baseline fibrinogen level is known, the dose should be individually calculated for each patient Although cryoprecipitate is the most commonly used replacement material, pathogen-reduced fibrinogen concentrates have several advantages, most importantly a lower potential risk of viral transmission and standardized fibrinogen content allowing accurate dosing

Cryoprecipitate indications and patterns of use in the

Indications for early fresh frozen plasma, cryoprecipitate

Cryoprecipitate is often used to restore fibrinogen levels in the management of symptomatic intracranial hemorrhage after rt-PA administration, despite limited published evidence. 21 Cryoprecipitate has several limitations, including the need for ABO matching, delay in administration due to product thawing, and concerns regarding potential. OVERVIEW important indications doses blood product compatibilities IMPORTANT INDICATIONS Packed red blood cells (PRBCs) Hb <100 and high risk of myocardial ischemia severe anemia (e.g. Hb<70) major active bleeding and Hb<100 Platelets <10 <20 and high risk (fever, neutropenia, antibiotics, risk of intracranial haemorrhage) <50 and active bleeding or requires invasive procedure <80 and requires.

Cryoprecipitate transfusion - WikE

Transfusion of whole blood and fractionated blood components is a widespread method for managing numerous conditions. Packed RBCs. are the most commonly transfused products and are primarily used for the treatment of acute or chronic blood loss. The rationale behind Introduction and Conclusions. Fresh Frozen Plasma (FFP) is defined as the fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 C (or colder) within 6 hours of collection Transfusion Medicine, 2010, 20, 48-61 doi: 10.1111/j.1365-3148.2009.00963.x ORIGINAL ARTICLE Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system M. El-Ekiaby,1 M. A. Sayed,2 C. Caron,3 S. Burnouf,4,5 N. El-Sharkawy,7 H. Goubran,8 M. Radosevich,6 J. Goudemand,3 D. Blum,4,5 L. de Melo,9 V. 1) Liver disease. 2) Bleeding out all components (i.e. massive transfusion protocol) 3)Active bleeding in a patient on warfarin. 4) Pt on warfarin requiring an urgent procedure that cannot wait for Vit K to take effect. (for 3 & 4: if INR is <9, no FFP, hold warfarin and give Vit K..... OR give Kcentra